Murphy W M, Rivera-Ramirez I, Medina C A, Wright N J, Wajsman Z
Department of Pathology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, USA.
J Urol. 1997 Dec;158(6):2102-6. doi: 10.1016/s0022-5347(01)68167-9.
Tests to detect recurrent bladder neoplasms are limited and none is consistently accurate. Recent studies suggest that the bladder tumor antigen (BTA) test, an agglutination reaction for basement membrane complexes, is superior to voided urine cytology in clinical practice. We compared BTA and voided urine cytology to bladder washings and cystoscopy, emphasizing diagnostic yield among patients with causes of basement membrane complexes other than bladder cancer.
Random voided urine specimens from 67 patients with a history of bladder neoplasms were collected before cystoscopy and bladder washing. Urine also was obtained from 34 patients with inflammatory bladder conditions including 5 with a history of prostate cancer. Each urine was tested for BTA according to a commercial kit. Positive results were indicated by yellow on a test pad. Blinded to all other results, each urine and each bladder washing were examined microscopically, and a positive test had malignant/suspicious cells. Bladder biopsies were performed when endoscopic lesions were seen. Specimens were grouped into 4 categories: group 1--biopsy proved bladder neoplasm, group 2--history of bladder cancer but not biopsy proved, group 3--history of prostate cancer and group 4--no history of urological cancer.
Voided urine cytology was positive in 54% of specimens from patients with biopsy proved bladder neoplasms compared to 29% for BTA. Relative yield for voided urine cytology versus BTA was not changed if all group 2 cases having a positive bladder washing and positive cystoscopy were assumed to have bladder cancer, nor was relative yield altered by subsequent short-term followup. Of voided urine specimens 14% from group 1 patients and 41% from group 2 patients had scant cells. Overall diagnostic yield was superior for bladder washing. False-positive BTA occurred in 7 of 34 patients with no history of urological or prostate cancer. There were no false-positive voided urine cytology interpretations in these groups.
BTA is not superior to voided urine cytology in detecting bladder neoplasms and may be limited by false-positive reactions in patients with other causes of basement membrane complexes in urine. Voided urine samples may be limited by high frequency of hypocellularity. Of 34 patients with a hypocellular urine specimen 4 had biopsy proved bladder cancer. Bladder washing yields best results but requires instrumentation. No test, including cystoscopy, is accurate always.
检测复发性膀胱肿瘤的试验有限,且无一始终准确。最近的研究表明,膀胱肿瘤抗原(BTA)试验,一种针对基底膜复合物的凝集反应,在临床实践中优于尿脱落细胞学检查。我们将BTA和尿脱落细胞学检查与膀胱冲洗液检查及膀胱镜检查进行比较,重点关注除膀胱癌外有基底膜复合物相关病因的患者的诊断率。
在膀胱镜检查和膀胱冲洗前,收集67例有膀胱肿瘤病史患者的随机晨尿标本。还从34例有膀胱炎症的患者中获取尿液,其中5例有前列腺癌病史。根据商用试剂盒对每份尿液进行BTA检测。检测垫上呈黄色表明结果为阳性。在对所有其他结果不知情的情况下,对每份尿液和每份膀胱冲洗液进行显微镜检查,阳性检测结果为有恶性/可疑细胞。发现内镜病变时进行膀胱活检。标本分为4类:第1组——活检证实为膀胱肿瘤,第2组——有膀胱癌病史但活检未证实,第3组——有前列腺癌病史,第4组——无泌尿系统癌症病史。
活检证实为膀胱肿瘤的患者中,尿脱落细胞学检查在54%的标本中呈阳性,而BTA为29%。如果假定所有膀胱冲洗液和膀胱镜检查呈阳性的第2组病例都患有膀胱癌,尿脱落细胞学检查与BTA的相对检出率不变,短期随访后相对检出率也未改变。第1组患者的晨尿标本中有14%细胞数量稀少,第2组患者中有41%细胞数量稀少。总体诊断率膀胱冲洗液检查更佳。34例无泌尿系统或前列腺癌病史的患者中有7例BTA出现假阳性。这些组中尿脱落细胞学检查无假阳性结果。
在检测膀胱肿瘤方面,BTA并不优于尿脱落细胞学检查,且可能因尿液中存在其他导致基底膜复合物的病因的患者出现假阳性反应而受到限制。晨尿标本可能因细胞数量稀少的频率较高而受到限制。在细胞数量稀少的尿标本的34例患者中,4例活检证实患有膀胱癌。膀胱冲洗液检查结果最佳,但需要器械操作。没有一种检查,包括膀胱镜检查,能始终准确。